Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis.
Source check: Source checked. Not independent scientific confirmation.
Finding: Among 559 retrospectively studied patients with chronic-phase chronic myeloid leukemia treated with flumatinib, XGBoost predicted 12-month major molecular response (AUC 0.852). Adding CIRS-G comorbidity scoring produced the largest reported incremental AUC (0.078; p=0.006) among the evaluated scores. This single-center retrospective association may overestimate prospective validity.
Technology: XGBoost predicted 12-month major molecular response; SHAP interpreted nonlinear feature associations and interactions, while CCI, ACE-27 and CIRS-G scores were compared for incremental predictive value.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- XGBoost predicted 12-month major molecular response; SHAP interpreted nonlinear feature associations and interactions, while CCI, ACE-27 and CIRS-G scores were compared for incremental predictive value.
- Test and result
- The publisher abstract reports retrospective data from 559 patients treated during 2018–2024, XGBoost AUC 0.852 for 12-month major molecular response, and the largest incremental value when CIRS-G was added to the baseline model (ΔAUC 0.078, p=0.006). SHAP analyses were exploratory; the study notes that temporal variation and retrospective design may overstate prospective validity.
- Limitation / still unknown
- The single-center retrospective model does not establish prospective performance or clinical benefit; the authors caution that temporal variation may overestimate validity.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1849735/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.